

Numéro de demande

1503461

Numéro d'enregistrement

TMA856904

Type(s)

Mot

Catégorie

Marque de commerce

Statut de l'OPIIC

ENREGISTRÉE

Statut de TM5

ACTIF/ENREGISTREMENT/
émit et actif



La demande de marque a été enregistrée auprès de l'Office.

Produite

2010-11-12

Enregistrée

2013-08-02

Date d'expiration de l'enregistrement

2028-08-02

Propriétaire inscrit

ORX PHARMACEUTICAL CORPORATION
55 Town Centre Court
Suite 800
Toronto
ONTARIO M1P4X4

Documents

[Afficher les documents](#)

Historique des actions

Action	Date de l'action	Date d'échéance	Commentaires
Produite	2010-11-12		
Créé	2010-11-12		

Rubriques d'index

HYDROMATRIX
HYDRO MATRIX

Produits (Classe de Nice & Énoncé(s))

(1) Tablets and capsules used to administer orally ingestible controlled release pharmaceuticals. A typical tablet contains at least an active drug in intimate mixture with a least two pharmaceutical polymers. The essential feature is the utility of novel hydrostatic couple compositions acting in tandem to induce hydrostatic pressure within a matrix solid dosage form such as a tablet or pellet. This novel concept is based on the effect of a hydrostatic pressure modulating polymers within the core of the solid dosage form in which differential hydrostatic pressure is created by the interaction between two polymers (hydrostatic couple) produces a release controlling pressure for zero-order release of the active ingredient. The understanding and controlling of properties associated with the hydrostatic couple facilitates time-release delivery of a wide range of pharmaceuticals. This solid composition accommodates oral control release of a wide range of drugs and beneficial agents whose kinetics are usually difficult to control and deliver due to high drug loading and highly solubility. This oral solid composition is based on the active drug being embedded in a homogeneous mixture of two or more polymers referred as the hydrostatic couple components. Formulations can also be programmed to delay onset of drug release as well as deliver multiple drugs at different rates simultaneously. This oral solid composition is simple to implement, easy to scale-up, inexpensive and offers numerous advantages over other technologies geared towards similar goals.

5 - Pharmaceutiques et herbicides

Revendication(s)

Declaration of Use filed August 02, 2013

Formalisée	2010-11-19		
Recherche enregistrée	2011-03-28		
Premier rapport de l'examineur	2011-03-28	2011-09-28	
Correspondance créée	2011-07-14	2012-01-14	
Correspondance créée	2012-02-23	2012-08-23	
Correspondance créée	2012-05-03	2012-11-03	
Avis d'approbation envoyé	2012-11-05	2012-12-03	
Approuvée	2012-12-27		APPROVED BY PROGRAM EX200M1
Publiée	2013-01-16		Vol.60 Issue 3038
Admise	2013-05-03		
Avis d'admission envoyé	2013-05-03	2013-11-12	
Enregistrée	2013-08-02	2028-08-02	